UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 631

Sortiert nach

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

Journal of clinical oncology, 2013-06, Vol.31 (17), p.2128-2135

2013

Link zum Volltext

Verfügbarkeit prüfen

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

Journal of clinical oncology, 2012-09, Vol.30 (26), p.3234-3241

2012

Link zum Volltext

Verfügbarkeit prüfen

Comparison of younger and older breast cancer survivors and age‐matched controls on specific and overall quality of life domains

Cancer, 2014-08, Vol.120 (15), p.2237-2246

2014

Link zum Volltext

Verfügbarkeit prüfen

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations

Clinical cancer research, 2018-07, Vol.24 (13), p.3163-3175

2018

Link zum Volltext

Verfügbarkeit prüfen

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

Journal of clinical oncology, 2008-10, Vol.26 (28), p.4672-4678

2008

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Journal of clinical oncology, 2008-04, Vol.26 (11), p.1810-1816

2008

Link zum Volltext

Verfügbarkeit prüfen

Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199

Clinical cancer research, 2015-11, Vol.21 (22), p.5082-5091

2015

Link zum Volltext

Verfügbarkeit prüfen

Stromal heterogeneity may explain increased incidence of metaplastic breast cancer in women of African descent

Nature communications, 2023-09, Vol.14 (1), p.5683-5683, Article 5683

2023

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer

Journal of clinical oncology, 2005-02, Vol.23 (4), p.792-799

2005

Link zum Volltext

Verfügbarkeit prüfen

A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer

Breast cancer research : BCR, 2018-08, Vol.20 (1), p.82-82, Article 82

2018

Link zum Volltext

Verfügbarkeit prüfen

Targeting progesterone signaling prevents metastatic ovarian cancer

Proceedings of the National Academy of Sciences - PNAS, 2020-12, Vol.117 (50), p.31993-32004

2020

Link zum Volltext

Verfügbarkeit prüfen

Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers

Breast cancer research : BCR, 2019-08, Vol.21 (1), p.87-87, Article 87

2019

Link zum Volltext

Verfügbarkeit prüfen

Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy

NPJ breast cancer, 2017-07, Vol.3 (1), p.24-6, Article 24

2017

Link zum Volltext

Verfügbarkeit prüfen

The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer

Clinical cancer research, 2009-09, Vol.15 (17), p.5297-5302

2009

Link zum Volltext

Verfügbarkeit prüfen

ADAM8 is expressed widely in breast cancer and predicts poor outcome in hormone receptor positive, HER-2 negative patients

Cancer cell international, 2023-08, Vol.23 (1), p.165-165, Article 165

2023

Link zum Volltext

Verfügbarkeit prüfen

Clinical-Translational Approaches to the Nm23-H1 Metastasis Suppressor

Clinical cancer research, 2008-08, Vol.14 (16), p.5006-5012

2008

Link zum Volltext

Verfügbarkeit prüfen

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

The lancet oncology, 2012-10, Vol.13 (10), p.e427-e436

2012

Link zum Volltext

Verfügbarkeit prüfen

Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer

Clinical cancer research, 2011-01, Vol.17 (2), p.372-381

2011

Link zum Volltext

Verfügbarkeit prüfen

A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer

Clinical cancer research, 2005-05, Vol.11 (9), p.3369-3376

2005

Link zum Volltext

Verfügbarkeit prüfen

A Personalized, Dynamic Physical Activity Intervention Is Feasible and Improves Energetic Capacity, Energy Expenditure, and Quality of Life in Breast Cancer Survivors

Frontiers in oncology, 2021-04, Vol.11, p.626180-626180

2021

Link zum Volltext

Verfügbarkeit prüfen

Predicting fear of breast cancer recurrence and self-efficacy in survivors by age at diagnosis

Oncology nursing forum, 2012-05, Vol.39 (3), p.287

2012

Link zum Volltext

Verfügbarkeit prüfen

Redefining the Target: Chemotherapeutics as Antiangiogenics

Journal of clinical oncology, 2001-02, Vol.19 (4), p.1195-1206

2001

Link zum Volltext

Verfügbarkeit prüfen

Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer

NPJ breast cancer, 2022-02, Vol.8 (1), p.16-16, Article 16

2022

Link zum Volltext

Verfügbarkeit prüfen

Inflammatory breast cancer appearance at presentation is associated with overall survival

Cancer medicine (Malden, MA), 2021-09, Vol.10 (18), p.6261-6272

2021

Link zum Volltext

Verfügbarkeit prüfen

Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer

NPJ breast cancer, 2021-03, Vol.7 (1), p.29-7, Article 29

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 631

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(598)
Mit Volltextzugriff
(551)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

Comparison of younger and older breast cancer survivors and age‐matched controls on specific and overall quality of life domains

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199

Stromal heterogeneity may explain increased incidence of metaplastic breast cancer in women of African descent

Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer

A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer

Targeting progesterone signaling prevents metastatic ovarian cancer

Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers

Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy

The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer

ADAM8 is expressed widely in breast cancer and predicts poor outcome in hormone receptor positive, HER-2 negative patients

Clinical-Translational Approaches to the Nm23-H1 Metastasis Suppressor

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer

A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer

A Personalized, Dynamic Physical Activity Intervention Is Feasible and Improves Energetic Capacity, Energy Expenditure, and Quality of Life in Breast Cancer Survivors

Predicting fear of breast cancer recurrence and self-efficacy in survivors by age at diagnosis

Redefining the Target: Chemotherapeutics as Antiangiogenics

Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer

Inflammatory breast cancer appearance at presentation is associated with overall survival

Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer

Suchergebnisse filtern